Literature DB >> 17875844

Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials.

Marko B Lens1, Paul Nathan, Veronique Bataille.   

Abstract

OBJECTIVE: To determine the effectiveness of wide vs narrow excision margins in the treatment of primary cutaneous melanoma. DATA SOURCES: We conducted a search of MEDLINE and the Cochrane Controlled Trials Register as well as a manual search of the reference lists of all relevant papers. No language or date restrictions were applied. STUDY SELECTION: Only prospective randomized trials were included. DATA EXTRACTION: Two reviewers independently extracted the data from each study. Outcomes evaluated were local and locoregional recurrences and overall mortality. Data were analyzed using Cochrane Collaboration Review Manager software. DATA SYNTHESIS: Five randomized trials comprising 3313 participants were retrieved and analyzed. Pooled data showed no statistically significant difference in overall mortality when comparing wide vs narrow excision margins (odds ratio, 0.98; 95% confidence interval, 0.72-1.22; and test for overall effect of P = .88). There was no statistically significant difference in the occurrence of locoregional recurrence between 2 groups of patients (odds ratio, 1.18; 95% confidence interval, 0.98-1.41; and test for overall effect not significant at P = .08). Although statistically significant heterogeneity was not detected among included trials, there was considerable clinical heterogeneity.
CONCLUSIONS: Although this meta-analysis did not show any statistically significant difference between patients treated with wide or narrow excision margins insofar as overall mortality and locoregional and local recurrences, current evidence is insufficient to address the optimal excision margins for all types of melanomas. Further research is required to establish the appropriate local treatment for different types of primary melanoma and subgroups of patients.

Entities:  

Mesh:

Year:  2007        PMID: 17875844     DOI: 10.1001/archsurg.142.9.885

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

Review 1.  Mucosal malignant melanomas in head and neck surgery: a retrospective study of six patients and review of the literature.

Authors:  Astrid L D Kruse; Marc O Riener; Klaus W Graetz; Heinz-Theo Luebbers
Journal:  Oral Maxillofac Surg       Date:  2010-09

2.  Re-excision within a radius of 2 cm in patients with melanoma of the skin - sufficient for local oncological radicalness.

Authors:  Strahil Asenov Strashilov; Angel Danchev Yordanov; Mariela Borisova Vasileva-Slaveva; Assia Andrianova Konsoulova
Journal:  Arch Med Sci       Date:  2020-07-08       Impact factor: 3.707

3.  Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?

Authors:  Matthew C Perez; Felipe R de Pinho; Amanda Holstein; Daniel E Oliver; Syeda M H Naqvi; Youngchul Kim; Jane L Messina; Erin Burke; Ricardo J Gonzalez; Amod A Sarnaik; C Wayne Cruse; Evan J Wuthrick; Louis B Harrison; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2018-08-02       Impact factor: 5.344

4.  Thick melanoma: prognostic value of positive sentinel nodes.

Authors:  Lenka Vermeeren; Fred W C van der Ent; Prapto S H Sastrowijoto; Karel W E Hulsewé
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 5.  Controversies in the diagnosis and treatment of early cutaneous melanoma.

Authors:  O A Orzan; A Șandru; C R Jecan
Journal:  J Med Life       Date:  2015 Apr-Jun

6.  New Safety Margins for Melanoma Surgery: Nice Possibility for Drinking of "Just That Cup of Coffee"?

Authors:  Georgi Tchernev; Anastasiya Atanasova Chokoeva
Journal:  Open Access Maced J Med Sci       Date:  2017-06-11

7.  Management of malignant melanoma.

Authors:  Goo-Hyun Mun
Journal:  Arch Plast Surg       Date:  2012-09-12

8.  Margins in skin excision biopsies: principles and guidelines.

Authors:  Richa Ranjan; Lavleen Singh; Sudheer K Arava; Manoj Kumar Singh
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.